
Current Price | $9.49 | Mkt Cap | $1.3B |
---|---|---|---|
Open | $9.54 | P/E Ratio | -2.11 |
Prev. Close | $9.46 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $9.28 - $9.59 | Volume | 359,924 |
52-Wk Range | $7.72 - $31.55 | Avg. Daily Vol. | 1,457,051 |
Current Price | $9.49 | Mkt Cap | $1.3B |
---|---|---|---|
Open | $9.54 | P/E Ratio | -2.11 |
Prev. Close | $9.46 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $9.28 - $9.59 | Volume | 359,924 |
52-Wk Range | $7.72 - $31.55 | Avg. Daily Vol. | 1,457,051 |
The best Bull and Bear pitches based on recency and number of recommendations.
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about VIR.
Recs
Underpriced stock with a strong pipeline and an effective COVID-19 therapy that is selling well overseas.
Recs
In the short term I like Vir because the market is seriously undervaluing its COVID treatment.
https://www.fool.com/investing/2022/02/10/3-biotech-stocks-that-are-too-cheap-to-ignore/
It's possible that we'll develop "herd immunity" to COVID, and when we catch mutating strains in the future, we'll be asymptomatic. If so the future COVID revenues will probably dry up. But another possible future is that COVID continues to mutate, and continues to be a threat, for a long time. If that's the case, Vir is going to be a spectacular investment.
Regardless, the massive revenues for 2022 are a certainty. The drug has an EUA, and it's already been sold. And the FDA has withdrawn the EUA for its competitors, because they don't work on the Omicron mutation.
Glaxo is selling and manufacturing the drug, and Vir is taking almost 75% of the revenues from the sales. Vir will make billions this year, and at a $4 billion market cap, it's dramatically underpriced on that basis alone.
Vir is also the opposite of a one-hit wonder. It's got a whole platform full of interesting molecules, including one that might be an effective cure for hepatitis B. The risk/reward ratio for Vir is amazing right now. Bought shares this week.
Recs
Vir Biotech up 21% on coronavirus buying frenzy
Jan. 27, 2020 10:19 AM ET|About: Vir Biotechnology, Inc. (VIR)|By: Douglas W. House, SA News Editor
Thinly traded Vir Biotechnology (VIR +20.9%) is up up on almost a 4x surge in volume, albeit a relatively modest 514K shares, as the animal spirits continue to sweep up companies that may be positioned to benefit from the coronavirus outbreak.
The company has four technology platforms that it is leveraging to develop treatments for infectious diseases, including influenza and tuberculosis.
Find the members with the highest scoring picks in VIR.
slnoutperform (22.82) Score: +261.68
The Score Leader is the player with the highest score across all their picks in VIR.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
TheFall2021 | 93.47 | 1/21/2021 |
![]() |
5Y | $43.03 | -77.92% | +19.13% | +97.05 | 0 Comment | |
rodraxx | 76.52 | 10/26/2023 |
![]() |
5Y | $8.24 | +15.29% | +10.60% | +4.69 | 0 Comment | |
GoldMiner20 | < 20 | 9/11/2023 |
![]() |
5Y | $10.66 | -10.88% | +2.21% | -13.09 | 0 Comment | |
Tangoko | < 20 | 9/1/2023 |
![]() |
3M | $12.55 | -24.27% | +1.71% | -25.98 | 0 Comment | |
NextGenStock | < 20 | 7/20/2023 |
![]() |
5Y | $12.79 | -25.72% | +0.98% | -26.71 | 0 Comment | |
Madmykl | 94.69 | 3/3/2022 |
![]() |
5Y | $24.81 | -61.71% | +4.07% | -65.78 | 0 Comment | |
TMFGBudwell | < 20 | 1/10/2022 |
![]() |
5Y | $33.80 | -71.89% | -0.93% | -70.96 | 0 Comment | |
Bigsef77 | 48.89 |
|
![]() |
5Y | $13.08 | -27.37% | +48.24% | -75.61 | 1 Comment | |
77lucky | < 20 | 10/6/2021 |
![]() |
5Y | $34.24 | -72.25% | +6.66% | -78.91 | 0 Comment | |
Espi | < 20 | 7/15/2021 |
![]() |
1Y | $36.28 | -73.81% | +5.42% | -79.23 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.